The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Eli Lilly and Company (NYSE:LLY) also signed a $1.4 billion deal with Sangamo Therapeutics for CNS gene therapy in April 2025. Industry focus on genetic hearing loss treatments is growing ...

Eli Lilly and Company (NYSE:LLY) also signed a $1.4 billion deal with Sangamo Therapeutics for CNS gene therapy in April 2025. Industry focus on genetic hearing loss treatments is growing, with ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clinic.

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness. The AK-OTOF therapy ...